• Users Online: 211
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 40  |  Issue : 3  |  Page : 130-137

CD44 as a diagnostic and prognostic marker in Egyptian patients with non-Hodgkin lymphoma

1 Department of Clinical Pathology, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt
2 Department of Clinical Pathology, Ain Shams Faculty of Medicine, Ain Shans University, Cairo, Egypt

Correspondence Address:
A A Hasnaa
Clinical Pathology Department, Sohag University Hospital, Sohag
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-1067.164727

Rights and Permissions

Background CD44 is an adhesion molecule that plays a role in lymphocyte homing; it is a multifunctional cell surface molecule involved in cell proliferation, angiogenesis, presentation of cytokines, chemokines, and growth factors. Patients and methods This study was carried out on 50 newly diagnosed non-Hodgkin lymphoma patients (33 men and 17 women) and 20 healthy controls; the patients were divided into two groups: group I included 20 patients with stage I, II, and III non-Hodgkin lymphoma and group II included 30 patients with stage IV non-Hodgkin lymphoma. They ranged in age from 38 to 75 years; all patients were subjected to a clinical examination, a complete blood count, bone marrow aspiration, and immunophnotyping using monoclonal for CD44 in addition to a routine panel of different chronic lymphoproliferative disorders (CD19, CD5, CD10, CD20, CD22, CD23, SIgM, CD38, CD79b, FMC7, CD103, CD123, κ, and λ light chains). Results CD19, CD20, CD22, CD23, κ/CD19, CD5/CD19, CD10, CD123, and CD103 expression levels showed no statistically significant differences between group I and group II, using the Mann-Whitney U-test, whereas other investigations showed significant differences; these differences were highly significant in terms of gated cell count, CD79b, SIgM, FMC7, λ/CD19, and CD44 expression levels. There was a positive correlation with significant differences between CD44 and FMC7, lymphocytic count, and LDH, a positive correlation with significant differences between CD44 and gated cell count and SIgM, and a highly statistically significant correlation between CD44 and λ/CD19, FMC7, lymphocytic count, and platelet count. Sixty percent of CD44-positive patients in group II had lymph node enlargement compared with only 15% of CD44-positive patients in group I. Conclusion Strong CD44 expression appears to be a powerful prognostic indicator in adult non-Hodgkin's lymphoma, with no difference between male and female patients. It is associated with standard poor prognostic markers such as bone marrow infiltration.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded144    
    Comments [Add]    

Recommend this journal